DLC-1 gene deleted in cancers

• US 6,897,018 B1
• Filed: 08/23/2000
• Issued: 05/24/2005
• Est. Priority Date: 02/25/1998
• Status: Expired due to Fees

• Current Assignee: United States Department Of Health And Human Services
• Original Assignee: United States Department Of Health And Human Services
• Inventors: Thorgeirsson, Snorri S., Yuan, Bao-Zhu, Popescu, Nicholas
• Primary Examiner(s): Ungar, Susan
• Assistant Examiner(s): Davis, Minh-Tam
• Application Number:
  US09/644,947
• Time in Patent Office: 1,735 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 435/94, 536/23.1, 536/24.3, 536/24.31
• US Class Current: 435/6.14
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors

Abstract

A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.

Claims

1. A method of diagnosing liver cancer in a subject, comprising:

detecting a deletion comprising exon 2 of a nucleic acid encoding SEQ ID NO;

2 in a sample from the subject, wherein detection of the deletion comprising exon 2 of a nucleic acid encoding SEQ ID NO;

2 is indicative of liver cancer.

2. The method of claim 1, wherein the sample is a peripheral blood, a urine, a saliva, a tissue biopsy, a surgical specimen, or an autopsy sample.

3. The method of claim 1, wherein the detection is by an amplification reaction, a hybridization reaction, or a change in electrophoretic mobility.

4. The method of claim 1, wherein the detection is by amplification reaction, and the amplification reaction is polymerase chain reaction.

5. The method of claim 1, wherein the sample is a tissue biopsy, a surgical specimen, or an autopsy sample.